Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication from organ transplantation. PTLD usually manifests as a mass in the lymph node or an extranodal mass in solid organs, such as the liver, transplanted kidney, tonsil, bone marrow, or spleen. PTLD rarely involves the central nervous system (CNS); however, here we report a case of PTLD that manifested as a brain tumor after kidney transplantation. A 52-year-old man who started peritoneal dialysis due to autosomal dominant polycystic kidney disease, underwent kidney transplantation 4 years ago. After kidney transplantation, he took tacrolimus, mycophenolate mofetil, and steroids. He was admitted to our hospital, complaining of a severe headache. Brain magnetic resonance imaging showed a multifocal, irregular, and round enhancing mass in the left basal ganglia. He underwent a needle biopsy for the enhancing mass and the pathological diagnosis was diffuse large B cell lymphoma. After this mass was confirmed as PTLD by histologic diagnosis, the patient had a reduction in his immunosuppression regimen (including a change from tacrolimus to sirolimus) and was treated with chemotherapy for PTLD. After 20 days, the patient expired from sepsis. PTLD involving the CNS is a rare and serious complication associated with solid organ transplantation. PTLD should be included in the differential diagnosis of brain tumors in recipients of solid organ transplants.
Introduction
Posttransplant lymphoproliferative disorder (PTLD) is one of the life-threatening complications of organ transplantation. Its incidence varies, depending on the recipient's age, the type and intensity of immunosuppression, and the organ type transplanted. The incidence ranges from 1% after kidney transplantation to as high as 20% in small bowel recipients, and it is higher in children than adults (1) . Few studies refer to the incidence of central nervous system (CNS) involvement in PTLD. CNS involvement was found in one case of 14 PTLD patients after kidney transplantation (2) , and in 2∼7% of posttransplant recipients, according to the type of organ, in 500 autopsy cases (3) . Treatment recommendations are not clearly established (4, 5) and prognosis of primary CNS lymphoma is poor as compared to systemic PTLD(4-6). Here, we report a case of PTLD manifested as brain tumor after kidney transplantation.
Case Report
A 52-year-old man who had received peritoneal dialysis for 6 years due to autosomal dominant polycystic kidney disease undergone kidney transplantation 4 years ago. After kidney transplantation, he was treated with tacrolimus 5 mg daily, mycophenolate 1,250 mg daily, and deflazacort 3 mg daily. He was admitted to our hospital complaining of severe headache. At presentation, the patient was hemodynamically stable. On general neurologic examination, there were no abnormalities. Heart, lungs, and abdominal examination was unremarkable. Ophthalmologic examination did not show any evidence of infection, inflammation, or neoplastic process. Laboratory tests showed the following values: white blood cell count 8,630/μL; hemoglobin 13.2 g/dL; platelet count 213,000/μL; blood urea nitrogen 21 mg/dL; serum creatinine 1.1 mg/dL; lactate dehydrogenase 406.6 U/L; and tacrolimus level 6.0 ng/mL. Urinalysis showed red blood cell count of 8∼10 cells/high power field, negative for protein and white blood cell. Brain computed tomography showed brain tumor with adjacent edema and mass effect in left cerebral hemisphere ( Fig. 1 ). Brain magnetic resonance imaging showed multifocal irregular round enhancing mass in left thalamus, basal ganglia, periventricular white matter, midbrain, pons, and middle cerebellar peduncle (Fig. 2 ). He underwent a needle biopsy for left thalamic enhancing mass. Histological examination of the tumor specimen found uniform large lymphocytes and immunohistochemisty stain of CD20, CD79a was positive, Ki-67 proliferation was about 30% and glial fibrillary acidic protein was negative ( Fig. 3 ).
In tissue, Epstein-Barr virus (EBV) in situ hybridization was negative. Pathological diagnosis was diffuse large B cell lymphoma. Further laboratory results proved to be positive for EBV viral capsid antigen (VCA) IgG, EBV nuclear antigen IgG, and negative for EBV VCA IgM, EBV early antigen IgG, EBV polymerase chain reaction. Systemic fluorodeoxyglucose positron-emission tomography and systemic computed tomography showed no lesions other than the brain tumors. After confirmed as PTLD by histologic diagnosis, tacrolimus, mycophenolate, and deflazacort were discontinued. He was prescribed sirolimus 2 mg daily. He was treated with PTLD (methotrexate, procarbazine, vincristine, and dexamethasone). But he exipired after 20 days due to pneumonia sepsis.
Discussion
PTLD is the second most common malignancy after skin cancer among adult solid organ transplantation recipients. CNS involvement is rare, especially in isolation. A review of the Israel Penn International Transplant Tumor Registry indicated that 15% of patients with PTLD had CNS involvement; and, in half of those patients, the CNS was the only site of disease (7) . In our center, 12 patients were diagnosed with PTLD among 1,013 kidney transplantation patients. Our patient was the only one who was diagnosed with CNS-PTLD.
The time from transplantation to the diagnosis of primary CNS-PTLD is 4.4 years. Twenty-three percentage of patients developed primary CNS-PTLD more than 10 years after transplantation and 35% of patients developed primary CNS-PTLD within 1 year of transplantation (8) . In our center, the median time from transplantation to diagnosis of PTLD was 6.5 years. Our patient was diagnosed with CNS-PTLD 4 years after kidney transplantation.
The type and intensity of immunosuppression have been linked with PTLD risk. However, it is not clear which immunosuppressive agents are realted to PTLD risk. Wimmer et al. (9) noted that a triple immunosuppressive regimen including mycophenolate mofetil was considered to have the highest imposing impact on the posttransplant malignancies. Snanoudj et al. (10) also noted that several of their primary CNS-PTLD cases developed soon after immunosuppression regimens were changed to mycophenolate mofetil. However, Einollahi et al. (11) noted that the incidence of PTLD was significantly increased in patients receiving azathioprine when compared to patients receiving mycophenolate mofetil. Our patient received a triple immunosuppressive regimen including mycophenolate mofetil.
Histologically, monomorphic PTLD has a more advanced and aggressive form than polymorphic PTLD. Monomorphic PTLD consists of large, transformed, blastic cells with prominent nucleoli and basophilic cytoplasm. Most monomorphic PTLD can be classified as large B cell lymphomas under the revised European-American lymphoma classification (12) . Polymorphic PTLD has been defined as atypical lymphoid infiltrates consisting of a heterogeneous cell population reflecting the full range of B cell maturation. The predominance of monomorphic type over the polymorphic type (100% vs. 0%) has been reported in CNS PTLD (12, 13) . However, another study reported a contradictory result (21% vs. 79%) (10) . In our case, the patient was diagnosed with monomorphic type PTLD classified as large B cell lymphoma.
EBV infection is a risk factor for developing PTLD and 60∼80% of PTLD is positive for EBV infection. The provision of immunosuppressive therapy prevents cytotoxic T-lymphocytes to control proliferation of EBV-infected B-lymphocytes ultimately leading to transformation into PTLD (5) . Primary infection of a previously EBV-seronegative patient during immunosuppression has been identified as a significant risk factor for the development of PTLD. This may occur through natural exposure or through transmission from an EBV-infected graft in a seronegative recipient (14) . Our patient was not related to EBV infection.
There is no definitive treatment for CNS PTLD. The main treatment of CNS PTLD is reducing or discontinuing the immunosuppressive therapy. Chemotherapy such as cyclophosphamide, adriamycin, vincristine, and prednisolone and anti B cell antibody have been used in the treatment of non-CNS PTLD. However, CNS PTLD is considered resistant to these agents, because of the low drug permeability of the blood brain barrier (4) . Nonetheless, recent data suggest that earlier use of rituximab may have favorable outcome (5, 15) . Radiotherapy is usually effective used singly or in combination with other treatments. But modulation of immunosuppressive agents should always be considered before performing whole brain radiation (10, 12) .
In conclusion, PTLD involving CNS is a rare and serious complication associated with solid organ transplantation. PTLD should be included in the differential diagnosis of brain tumors in recipients of solid organ transplantation.
